Phio Pharmaceuticals Corp. (PHIO) stock
Close on Nov 11, 2026Market cap $9.45MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $9.45M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.10
- Dividend yield
- –
- Free cash flow yield
- -131.22%
Fundamentals
- Net income
- -$14.67M
- EPS, diluted
- -$1.31
- Free cash flow
- -$12.40M
- Book value per share
- $0.74
- Diluted shares
- 12M
Trading
- Next earnings
- Mar 4, 2027 (estimated, after the close)
- Previous close
- $0.81
- Open
- $0.82
- Day's range
- $0.80 – $0.86
- Volume
- 81,317
- Average volume (20 days)
- 67,986
- Beta (5 years)
- 1.38
- 52-week range
- $0.75 – $1.88
- RSI (14 days)
- 37.5
- Volatility (1 year)
- 78.3%
- Relative volume
- 0.19×
- WACC
- 11.8%
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PHIO | S&P 500 | Difference | PHIO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -16.9% | -2.4% | −14.5 pts | ||
| 3 months | -25.4% | -1.2% | −24.2 pts | ||
| Year to date | -22.6% | +12.3% | −34.8 pts | ||
| 1 year | -49.5% | +12.4% | −61.9 pts | ||
| 3 years | -91.6% | +78.8% | −170.4 pts | -56.3% | +21.4% |
| 5 years | -99.5% | +75.2% | −174.7 pts | -65.7% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -68.1% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Phio Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Results
- News
- Results
About Phio Pharmaceuticals
Pharmaceutical Preparations
Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company that develops immuno-oncology therapeutics to treat various forms of cancer. Its work centers on its proprietary INTASYL small interfering RNA gene-silencing technology, which enhances the capacity of immune cells to eliminate tumor cells without requiring specialized drug formulations or delivery mechanisms. The company operates within a single business segment, directing its pipeline toward cancer patients. Its investigational product candidates include PH-762, designed to target the PD-1 protein for the treatment of cutaneous carcinomas, and PH-894, designed to silence the BRD4 protein.
Company profile, executives and historyPhio Pharmaceuticals stock: common questions
What is Phio Pharmaceuticals's stock price?
PHIO closed at $0.81 on Nov 11, 2026, down 0.07% on the day. Over the past 52 weeks it traded between $0.75 and $1.88.
What is Phio Pharmaceuticals's market cap?
Phio Pharmaceuticals was worth $9.45M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PHIO's P/E ratio?
Phio Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.31), so it has no meaningful P/E ratio.
Does Phio Pharmaceuticals pay a dividend?
No. Phio Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Phio Pharmaceuticals report earnings next?
Phio Pharmaceuticals is expected to report Q4 FY2026 results on Mar 4, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has PHIO stock performed over the past year?
Including dividends, PHIO returned -49.5% over the past year, against +12.4% for the S&P 500.
How many PHIO shares are sold short?
0M shares were sold short at the latest FINRA report, 0.83% of the float, or 1.5 days of average trading volume.
Who are Phio Pharmaceuticals's competitors?
Companies most similar to Phio Pharmaceuticals by business, industry and size include PRLD, CLRB, XLO, KAPA, BOLD.
See a number that looks wrong?